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Introduction
 Alzheimer’s Disease (AD) is a complex 
neurodegenerative disease, with a present incidence of 
about 24 million in the global population, and 800,000 in 
the UK population. Current medications, which include 
acetyl cholinesterase inhibitors such as Aricept, and 
NMDA receptor antagonists [1], such as memantine, treat 
the symptoms but do not slow neurodegeneration [2]. 
Brain imaging studies with PET reagents that detect Aβ 
deposits [3] have shown that pathophysiological changes 
in patients with AD precede the manifestation of clinical 
symptoms by decades, suggesting that biomarkers may 
be useful in prediction of the disease in people with mild 
cognitive impairment (MCI), or prodromal AD, who are 
yet to develop measurable cognitive symptoms. Deposition 
of the peptide β-amyloid has been cited as a prime possible 
cause of the neurodegeneration seen in the disease. This 
40-42 residue peptide is released by proteolysis from its 
transmembrane precursor protein APP, and aggregates in 
stages. First β-amyloid forms small soluble oligomers, 
then larger soluble protofibrils and finally precipitates as 
insoluble protofibrils or fibrils, which are components of 
the plaques seen in post-mortem sections from brains of 
Alzheimer’s patients [4]. Dimers of β-amyloid have been 
shown to block long-term potentiation and reduce dendritic 
spine density in the rat hippocampus [5]. The Dutch 
cerebral haemorrhage mutated form of Aβ is also studied. 
Hereditary cerebral haemorrhage with amyloidosis, Dutch 
type (HCHWA-D), is a cerebral amyloidosis characterized 
by prominent vascular deposits and fatal haemorrhages. 
The disorder is caused by a point mutation in codon 693 
of the gene encoding the amyloid precursor protein (APP), 
resulting in a Glu-->Gln amino acid substitution at position 
22 of the amyloid beta-protein (Aβ) region The 
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 Oligomeric forms of the peptide, β-amyloid, (Aβ) are known to be toxic to human and rodent 
neurones, and have been identified as possible causative agents in the loss of cognitive function in 
Alzheimer’s Disease (AD). An ELISA assay has been developed capable of detecting oligomeric forms 
of Aβ in biological fluids, but not detecting monomeric species. The ELISA has been validated with a 
number of synthetic variant sequences of Aβ and the effects of known inhibitors of Aβ oligomer formation. 
Significantly raised levels of oligomers were detected in sera samples from AD patients, compared to age-
matched control sera.
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crossed β-structure of β-amyloid in fibrils gives rise to 
the characteristic birefringence seen  in post-mortem 
AD brain  sections stained with Congo red. Therapy 
involving vaccination against β-amyloid has shown some 
success in early, moderate Alzheimer’s patients, and is in 
clinical trials, and a number of other strategies that lead 
to decreased β-amyloid production are under investigation 
[6]. Reliable biomarkers are essential for detection of signs 
of AD at the prodromal or MCI stages, when treatment and 
prevention are likely to be most effective. Biomarkers are 
generally measured in body fluids, such as CSF and blood, 
but images collected as a result of MRI or PET scanning 
of brain, are also useful biomarkers.  The possibility is 
arising of asymptomatic treatment for Alzheimer’s at the 
preclinical stages, when Aβ in the aggregated form is 
accumulating, to prevent irreversible neuronal damage 
that occurs gradually, leading to cognition and memory 
problems. An economical and reliable blood test for Aβ 
aggregates at the preclinical stages, would enable screening 
of large numbers of people, leading to further analyses of 
CSF samples, supplemented with confirmatory PET brain 
scans for deposited brain Aβ and/or hyperphosphorylated 
versions of the microtubule-associated protein tau 
aggregated into neurofibrillary tangles, on selected at-risk 
individuals. Uptake of the PET tau reagent into the medial 
temporal lobe has been correlated with loss of memory 
performance in older individuals [7]. 
Materials and Methods
Solid-phase ELISA
 A non-competitive direct solid-phase ELISA assay 
was developed which allows the selective measurement of 
the oligomerisation of Aβ peptides in solution. The assay 
involves an antibody raised against the N-terminus of the 
Aβ peptide sequence, and is used in the same assay in both 
the biotinylated and non-biotinylated forms. The assay 
detects oligomers as N-terminal epitopes of β-amyloid. Aβ 
oligomers bind to the non-biotinylated antibody-coated 
wells and then the biotinylated form of the antibody binds 
to additional N-terminal epitopes present in oligomers. 
The levels of bound biotin are measured after the addition 
of peroxidase-avidin, by the colour change produced 
on addition of peroxidase substrate. Monomers are not 
detected as the biotinylated antibody is not able to bind 
the single epitope already occupied by binding to the non-
biotinylated anti-NTA4 antibody immobilising Aβ to the 
wells.
Preparation of  Antibodies.  
 Affinity-purified anti-NTA4 antibody prepared 
by immunisation of rabbits with an N-terminal 10-residue 
synthetic peptide sequence of Aβ, affinity purified 
on immobilised peptide, and preservation in 0.05% 
thiomersal/PBS at-20oC was prepared as described in [8].
Preparation of Biotinylated Anti-NTA4
 Anti-NTA4, an affinity-purified polyclonal rabbit 
antibody raised to the N-terminal ten residues of the Aβ-
peptide, (NTA4) [8] was biotinylated. The affinity-purified 
antibodies stored at -20oC in PBS were isolated from 
thiomersal preservative by gel filtration on a Sephadex 
G-25 gel column in 0.1M sodium borate buffer, and re-
concentrated to 0.3mg/ml using a microcentrifuge filter 
(Centisart-C4). N-Hydroxysuccinimide biotin-caproate 
(Sigma-Aldrich; B2643) in a stock solution of 10mg/ml 
in dimethyl sulfoxide was added to the antibody solution 
to give a molar excess over antibody of 165. The mixture 
was incubated on a rotating wheel at 20oC for 4 hours. 20μl 
of 1M ammonium chloride was then added to quench the 
reaction, and incubation continued at room temperature for 
10 minutes. The mixture was then subject to gel filtration 
on Sephadex G-25 in PBS to remove any excess uncoupled 
biotin. The biotinylated antibody was collected and stored 
in 200μl aliquots at -20oC. 
ELISA Assay 
 An ELISA plate was coated with 5μg /ml of 
non-biotinylated anti-NTA4 antibody (100μl /well), in 
PBS/0.05% sodium azide at 4oC for 24 hours. Any excess 
antibody remaining was decanted. The plate was then 
washed twice with blocking buffer (PBS/1% BSA/0.05% 
Tween (pH 7.4)), and incubated with blocking buffer for 
1 hour at room temperature to block any unreactive sites 
and to prevent the stacking of several layers of antibody. 
Excess blocking buffer was decanted, and  dilutions of Aβ 
solutions to be assayed, prepared in blocking buffer, then 
added (100μl /well). The plate was incubated at 37oC for 
2 hours. After washing four times with blocking buffer, 
100μl biotinylated anti-NTA4 antibody, diluted 1 to 500 
in blocking buffer, was added to each well, and incubated 
at 37oC for 1.5 hours. Wells were washed with blocking 
buffer three times and incubated with extraavidin-
peroxidase (E2886; Sigma) diluted 1 to 2000 in blocking 
buffer (100μl /well) at 37oC for 1.5 hours. The plate was 
washed twice with blocking buffer and three times with 
PBS/0.05% Tween before adding substrate for peroxidase, 
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TMB Chromagen, (Thermo-Fisher)(100μl per well). A 
colour change was allowed to develop for 7 to 10 minutes. 
1M H2SO4 (100μl /well) was then added to the plate, and 
the plate was read on an ELISA reader at 450nm [9].
Peptides
 Five synthetic Aβ peptides used in the experiments 
were synthesised on solid-phase using the Fmoc method on 
a Milligan 9050 peptide synthesiser [10] and then purified 
on HPLC.
1. Aβ1-40  The sequence is shown below:
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM
VGGVV
2. Aβ1-42  The sequence is shown below:
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM
VGGVVIA
3. E22Q Aβ The underlined E residue in the Aβ1-42 
sequence is mutated to Q in E22Q, the sequence found in 
patients with Dutch Cerebral Haemorrhage (E22Q).
4. Y10orthoNO2Y Aβ  The nitrosylated form of Aβ has 
a nitro group on residue Y in position 10 of the Aβ1-40 
sequence. Nitro-tyrosine residues are found in the region 
of senile plaques when Aβ reacts with copious amounts of 
nitric oxide and superoxide present in these lesions.
5. N-Terminal peptide DAEFRHDSGY (residues 1 to 10 
of the N-terminal of the Aβ peptide, NTA4)
 Aβ1-40, E22Q Aβ and nitrosylated Aβwas 
prepared in sterile distilled water followed by addition of 
a 10% volume of sterile 1M Tris-HCl (pH 7.4) to obtain 
their final concentrations. Aβ1-42 was dissolved in 10mM 
NaOH and sterile distilled water added, followed by a 
10% volume of sterile 1M Tris-HCl (pH 7.4) to obtain the 
required concentration of Aβ1-42. 
Inhibitors
 Synthetic peptide inhibitors were tested to see 
whether they inhibited the formation of oligomers. The 
synthetic peptide inhibitors tested include Om1, Om2, 
acetylated Om1 (AcOm1), acetylated Om2 (AcOm2), and 
retro-inverse Om2 (RIOm2), which is the D-form of Om2 
(lower case letters represent D-amino acids). They were 
synthesised on solid-phase using the Fmoc method on a 
Milligan 9050 peptide synthesiser and then purified on 
HPLC, as described in [11]. Inhibitors were made up to 
required concentrations in sterilised distilled water. Their 
sequences are shown below [11]:
Om1   RGKLVFFGR  
AcOm1   AcRGKLVFFGR  
Om2   RGKLVFFGR-NH2
AcOm2   AcRGKLVFFGR-NH2
RIOm2   rGffvlkGr-NH2
Sites and Subject Recruitment
 44 consecutive patients attending memory clinics 
in Barnes Hospital, with a diagnosis of AD were recruited 
for this study, along with 16 age-matched carer controls, 
were consented for the study according to the protocol in 
“Proteomic studies of Alzheimer’s Disease”, passed by the 
St George’s Healthcare Ethics Committee, in Sep, 2004. 
Blood samples (5.0ml) were collected from 44 Alzheimer’s 
patients, aged 65+ (ICD10 and NINCDS criteria; [12]) 
and 16 age-matched controls with no recorded memory 
problems, who had accompanied patients to the clinics. 
Blood was obtained by venepuncture, transferred to 
centrifuge tubes, incubated at room temperature for 15 
mins to clot, and then centrifuged in a bench centrifuge 
at 2000xg for 15 mins. The clear supernatant serum was 
transferred to 1.5ml polypropylene tubes, on ice, stored 
at -20oC for two weeks, then transferred at -20oC to a 
-70oC freezer. On the same day as assay, samples were 
thawed by warming rapidly to room temperature, some 
samples diluted 1 to 100 with blocking buffer (PBS/1% 
BSA/0.05% Tween (pH 7.4)),  before subjecting to the 
Elisa measurement for oligomers. 
Western Blotting
 Sera samples from Alzheimer’s patients and 
control patients were removed from the -70o C freezer and 
left to thaw on ice. Once thawed 10 µl of sample was added 
to 20 µl of tricine sample buffer containing dithiothreitol 
(Invitrogen). Samples were then vortexed and heated for 
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about 5 minutes at 95o C. Equal volumes (25μl) were 
electrophoresed on 16% Tricine gels (Invitrogen), together 
with samples of synthetic Aμ42, or low molecular weight 
markers (Invitrogen). After electrophoresis, proteins were 
transferred to PVDF membrane by transverse semi-dry 
electrophoresis. After transfer, the membrane was placed 
into a 50 ml falcon tube, completely covered  with PBS 
and placed in a boiling water bath for ten minutes. The 
membrane was left to cool and then washed twice (five 
minutes each wash) in PBS Tween (0.05% v/v). A western 
blocking buffer was prepared by measuring out 2.5g of 
milk powder and adding this to 50ml of PBS Tween. The 
membrane was then put into 10ml of this blocking buffer 
and left for an hour on the rocker. Primary antibody was 
anti-mouse Aβ 6E10 (Covance) monoclonal antibody, 
diluted 1 to 1000 in blocking buffer, and secondary anti-
mouse IgG linked to peroxidase (Sigma) diluted 1 to 2000 
in blocking buffer.
Results
 An ELISA was designed to detect soluble oligomers 
of β-amyloid. The assay used anti-NTA4, an antibody to 
the N-terminus of β-amyloid to attach oligomers of Aβ to 
wells in an ELISA plate and further epitopes present in 
oligomers were detected by biotinylated form of the anti-
NTA4 antibody. The response of the ELISA, as measured 
by the absorbance values obtained at 450nm shows the 
amount of soluble oligomers present in solution. The 
higher the value of absorbance, the greater the level of 
oligomerisation. 
Comparison of Aβ1-40, E22Q Aβ, and Nitrosylated 
Aβ
 The response of fresh and aged solutions of Aβ1-
40, E22Q Aβ, and nitrosylated Aβ (NO2) were compared 
(figure 1). Wells of a plate were coated with either 
unbiotinylated anti-NTA4 or control rabbit IgG antibody. 
 Wells of a plate were coated with either non-
biotinylated anti-NTA4 antibody or control rabbit IgG 
(0.5μg/ml in PBS/azide) and left overnight at 40C before 
removal. Wells were washed in PBS, then fresh peptide 
solutions of Aβ1-40, E22Q Aβ, and NO2 Aβ were prepared 
in sterilised distilled water, to which a 10% volume of 
sterile 1M Tris-HCl (pH 7.4) had been added to give a 
final concentrations of 5μg/ml, and tested in the ELISA 
immediately. Aged solutions were prepared in the same 
way but were incubated at 370C for 1 hr before testing. 
Wells were washed with 1xPBS/1% BSA/0.05% Tween 
buffer, and the ELISA developed with biotinylated NTA4 
as described in Methods above... The mean of triplicate 
measurements and the standard deviation for each sample 
are shown.
 The graph shows that fresh samples of Aβ1-40, 
E22Q Aβ and NO2 Aβ gave much lower responses than Aβ 
solutions that had been aged at pH 7.4. When the peptide 
solutions were added to wells coated with control rabbit 
IgG, the response was much lower for both aged and 
fresh samples – there was no more response than in wells 
coated with either anti-NTA4 or rabbit IgG to which no Aβ 
peptide had been added. 
 From the ELISA response of wells coated with 
anti-NTA4, it can be seen that aged Aβ1-40 solutions 
contained higher levels of oligomers than aged E22Q Aβor 
NO2 Aβ. As the ELISA response of fresh E22Q Aβ was 
higher than that of Aβ, it seems that the Dutch mutated 
peptide formed oligomers more rapidly and greater extent 
than native Aβ E22Q. 
Comparison of Aβ1-40, Aβ1-42 and E22Q Aβ 
Oligomer Formation Over Time
 An assay was carried out to look at how the levels 
of soluble Aβ oligomers in solution vary over a 20-hour 
period of incubation of the Aβ peptides. Fresh samples of 
Figure 1: ELISA response using antibody to peptide NTA4 (anti-
NTA4), compared to control non-specific Rb IgG as coating antibodies, 
with aged or fresh solutions of Aβ(1-40) peptides, followed by detection 
of multiple epitopes by biotinylated NTA4. 
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Aβ1-40, Aβ1-42 and E22Q Aβ were prepared and then 
incubated in 0.1M Tris at pH7.4, with samples being taken 
at different times over a 20-hour period. Rabbit IgG coated 
wells containing just Aβ1-42 were used as controls. 
 The amounts of oligomer formed from Aβ1-40 
was maximum after the first 5 hours of pre-incubation, 
with a slight further increase at 20 hours. E22Q oligomers 
were formed more rapidly, reaching their maximum level 
after just 20 minutes of pre-incubation. Slight decreases 
were measured up to 20 hours, indicating that further 
changes such as precipitation may have occluded the 
epitopes. Aβ1-42 oligomers were at high levels after short 
periods of incubation, rising rapidly in the first 20 minutes, 
followed by a further slight increases up to 5 hours, than 
a decline after 20 hours incubation, indicating that some 
epitopes in the aggregates were also occluded, perhaps by 
precipitation. Low absorbance values were achieved with 
Aβ1-42 added to control rabbit IgG coated wells.
 It was interesting to see that the ELISA responses 
from solutions of Aβ1-42 and E22Q Aβ decrease after 5 
hours pre-incubation, possible caused by precipitation 
of aggregates. This precipitation of the peptide probably 
impedes the binding of biotinylated NTA4 antibody as 
the epitopes are occluded, decreasing the response of the 
assay. 
 The data suggests that the rates of oligomerisation 
between the peptides differ, with Aβ1-42 and E22Q Aβ 
forming oligomers at the fastest rate, and Aβ1-40 the 
slowest. The high absorbance of Aβ1-42 solutions at 
the beginning of incubation, after 3 mins, suggest that 
oligomers are formed immediately when Aβ1-42 is diluted 
into blocking buffer.  
 It was decided to compare Aβ1-42 oligomer 
formation in solutions prepared by dilution into Tris 
from NaOH with Aβ1-42 oligomers prepared in the 
disaggregating solvent DMSO. It was thought that if any 
oligomers were present in Aβ1-42 before it was made 
soluble, DMSO would convert them into monomers.
Fresh samples of Aβ1-40 and Aβ1-42 were prepared 
as described in the methods. Aβ1-42 was dissolved in 
DMSO (100 v/w) and sterilised water was added followed 
by addition of a 10% volume of sterilised 1M Tris-HCl 
(pH 7.4) to obtain the required concentration. Solutions 
were aged, and samples taken over a 20-hour period, and 
subjected to the ELISA after dilution into blocking buffer. 
Aβ1-40 was used as a control.
Figure 2: Wells of a plate were coated with either non-biotinylated anti-
NTA4 or control rabbit IgG (5ug/ml). Samples of Aβ1-40, Aβ1-42 and 
E22Q Aβ ) (0.5mg/ml), were prepared as described in the methods and 
then incubated at 370C. At time points of 0 minutes, 20 minutes, 1, 2, 
5, and 20 hours, samples of the peptide solutions were removed and 
diluted 1 to 800 in cold (+4oC) 1xPBS/1% BSA/0.05% Tween buffer. 
All three peptides were added to the NTA4 coated wells, but only Aβ1-
42 was added to the rabbit IgG coated wells to act as a control. The 
remainder of the ELISA was performed as described in the methods. 
The mean of triplicate measurements and the standard deviation for 
each time point is shown.
Figure 3: Wells of a plate were coated with non-biotinylated anti-
NTA4 antibody and left overnight at 40C. 0.5mg/ml samples of Aβ1-40 
and Aβ1-42 were prepared in 0.1M Tris (pH 7.4) as described in the 
methods. Aβ1-42 was also prepared in 0.1M NaOH or DMSO (50% 
w/v) and sterilised distilled water (50%w/v) followed by addition of 
10% volume of sterilised 1M Tris-HCl (pH 7.4) to give a concentration 
of Aβ1-42 of 0.5mg/ml. The peptides were incubated at 370C. At 
time points of 0 minutes, 20 minutes, 1, 2, 5, and 20 hours samples 
of the peptide solutions were taken and diluted 1 to 800 in 1xPBS/1% 
BSA/0.05% Tween buffer... The remainder of the ELISA was performed 
as described in the methods. The mean of triplicate measurements and 
the standard deviation for each time point is shown.
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 The high absorbance of fresh Aβ1-42 was not 
affected by predissolving it in DMSO (figure 3). The 
absorbance value of Aβ1-42 when initially dissolved in 
DMSO and diluted to 0.1M Tris was as high as when intially 
dissolved in NaOH. It likely that oligomers are formed 
from DMSO when it is diluted in the PBS/1%BSA/0.05% 
Tween, a solution which is compatible with the ELISA 
test. Aβ1-40 showed a similar response to the previous 
experiment, reaching a maximum concentration of 
oligomers after about 4 hours incubation, increasing 
slightly to 20 hours. The results here suggest that Aβ1-
42 forms oligomers at a much faster rate than Aβ1-40, 
occurring immediately when it is put into solution in 0.1M 
Tris (pH7.4). 
Comparison of Aβ1-40 and Aβ1-42 at Different 
Concentrations
 It was decided to compare the oligomerisation 
rates of Aβ1-40 and Aβ1-42 at different concentrations 
over a 20-hour time period. Fresh solutions of the peptides 
were prepared at concentrations of 0.2 and 0.05mg/ml, and 
then aged at 370C. A peptide, the N-terminal 10 residues of 
Aβ, pre-incubated under the same conditions was used as 
a control.
 Solutions of Aβ1-40 at 0.05mg/ml showed a 
gradual increase in binding biotinylated antibody as 
the time of pre-incubation was increased (figure 4). The 
same is true at a concentration of 0.2mg/ml. In contrast 
to Aβ1-40, Aβ1-42 gave high absorbance values initially, 
which increased by only 15% as the pre-incubation time 
was increased. Solutions incubated at 0.2mg/ml gave 
only slightly more oligomers than solutions incubated 
at 0.05mg/ml. A control peptide, NTA4 containing the 
N-terminal ten residues of Aβ, which binds the anti-NTA4 
antibody, but does not oligomerise, did not increase in 
absorption in the ELISA upon incubation.
 It seems that peptides at a higher concentration 
have an increased rate of oligomerisation and produce 
high levels of soluble oligomers. Thus the process of 
oligomerisation is dependent upon concentration. 
Inhibitory Activity of Synthetic Peptides on Aβ 
Oligomerisation
 The  aim of these assays was to characterise 
oligomer formation by including peptides  previously 
shown to inhibit cellular toxicity of both Aβ1-40 and Aβ1-
42 [11]. Fresh peptide mixtures of Aβ1-40 and peptide 
inhibitors Om1, AcOm1, Om2, and AcOm2 [11] were 
prepared. The inhibitor solutions were incubated with 
Aβ1-40 in an equimolar ratio and then assayed. Aged 
Aβ1-40 incubated in the absence of inhibitor was used as 
a control, as were the peptide inhibitors on their own (no 
Aβ). 
Figure 4: Solutions of Aβ1-40 and Aβ1-42 at 0.2mg/ml or 0.05mg/ml, 
prepared as in methods, were incubated at 370C. The N-terminal 10 
residues of Aβ were incubated under the same conditions and used as a 
control. At time points of 0 minutes, 20 minutes, 1, 2, 5, and 20 hours 
a sample of the peptide solutions was taken and diluted 1 to 800 in 
1xPBS/1% BSA/0.05% Tween buffer. Samples were incubated on an 
ELISA plate already coated with immobilised anti-NTA4 antibody. The 
remainder of the assay was performed as described in the methods. The 
mean of triplicate measurements and the standard deviation for each 
time point is shown.
Figure 5: Wells of a plate were coated with non-biotinylated anti¬NTA4 
antibody and left overnight at 40C. Freshly prepared peptide solutions 
of Aβ1-40, Om1, AcOm1, Om2, and AcOm2 were prepared in sterile 
distilled water, to which a 10% volume of sterilised 1M Tris-HCI 
(pH 7.4) was added to give a peptide concentration of 2mg/ml. Equal 
volumes of each inhibitor and Aβ1-40 were added to each other so the 
final concentration of the peptide and inhibitor solution was 1mg/ml. 
Aged Aβ1-40 and inhibitors on their own (all at 1 mg/ml) were also 
prepared to act as controls. All solutions were incubated at 370C for 2 
hours. Results are reported after serial dilution to 1μg/ml of Aβ, using 
both fresh and aged samples, were prepared in 1xPBS/1% BSA/0.05% 
Tween buffer. The ELISA was performed as described in the methods. 
The mean of triplicate measurements and the standard deviation for 
each peptide point are shown.
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 The results show that compared to the control 
of Aβ1-40 pre-incubated on its own, Om1 and AcOm1 
increase the amount of oligomerisation of Aβ1-40, rather 
than inhibit (figure 5). Om2 and AcOm2 in contrast 
decrease aggregation of Aβ1-40. Overall it can be seen 
that the non-acetylated inhibitors are more effective at 
reducing the level of oligomerisation than the acetylated 
forms, and Om2 RGKLVFFGR-NH2, the amidated form, 
is more effective than Om1, RGKLVFFGR Thus the most 
effective of the synthetic peptides tested here is non-
acetylated Om2. 
 Since Om2 had been found to be the most effective 
synthetic peptide, it was synthesised in the retro-inverted 
form, (rGffvlkGr-NH2), (lower case letters represent 
D-forms of amino acids), in which the native sequence 
is inverted, and compared for inhibitory activity on both 
Aβ1-40 and Aβ1-42 oligomer formation, and at a greater 
range of peptide: inhibitor ratios (results are shown in 
[13]). The retroinverted form, RIOm2, was more resistant 
to proteolytic degradation than the naturally occurring 
L-form [13], and may therefore serve as the basis of a 
preferred drug in vivo rather than  the native L-form. 
 Peptides Aβ1-40 and Aβ1-42 with inhibitors Om2 
and RIOm2 were tested at a range of peptide: inhibitor 
molar ratios (1:1, 2:1, 4:1, 8:1, and 16:1) with Aβ peptide 
concentration constant. Aβ1-40 and Aβ1-42 solutions 
were also prepared on their own to act as controls. Each 
solution was aged for 20 hours after an initial sample had 
been taken.
 It was found that pre-incubated solutions gave a 
higher absorbance value than fresh for both A peptides 
(figure 6). Fresh values of Aβ1-42 were again much higher 
than fresh values of Aβ1-40. This was consistent with 
previous experiments. The values of both fresh solutions 
of peptides were unaffected by the addition of inhibitors, 
suggesting that the inhibitory effect is not immediate.
 Comparing ELISA response of Aβ1-40 pre-
incubated with RIOm2 it can be seen that the inhibitor is 
most effective at peptide: inhibitor molar ratios of 1:1, 2:1 
or 4:1 (constant peptide concentration) reducing the ELISA 
response by 58%, 53%, and 55% respectively. It has little 
or no effect at ratios of 8:1 and 16:1. When RIOm2 was pre-
incubated with Aβ1-42 a similar effect is seen at peptide: 
inhibitor molar ratios of 1:1, 2:1 and 4:1. Om2 inhibits the 
ELISA response when pre-incubated with both Aβ1-40 
and Aβ1-42 at peptide: inhibitor ratios of either 1:1 (43% 
with Aβ1-40; 50% with Aβ1-42) or 2:1 (42% with Aβ1-
40; 51% with Aβ1-42). At peptide: inhibitor ratios greater 
than this it does little to inhibit oligomerisation of either 
Aβ peptides. Overall RIOm2 inhibits the ELISA response 
to a greater degree than Om2 especially at low peptide: 
inhibitor molar ratios. 
Elisa Measurement of Oligomers in Sera Samples 
of Alzheimer’s Patients and Controls
 Patients sera, or standard preincubated aged 
Aβ42 (1mg/ml) were diluted into blocking buffer and 
incubated in plates treated with antibody (NTA4), After 
24hr incubation at 4oC, plates were processed for by the 
ELISA described in the methods section. Aβ oligomer 
concentrations were calculated from measured ELISA 
ODs using known concentrations of Aβ42 as standard. 
The mean concentrations of oligomers in patients sera 
was determined as 53.49 + 9.14ng/ml,  whereas the mean 
concentration in age-matched controls was 23.03 + 7.55ng/
ml. The significance of the differences between the two 
groups was calculated as p=0.000652. 
 The serum levels of β-amyloid oligomers were then 
plotted as a receiver operating characteristic (ROC curve) 
(Figure 7) for two groups, patients and controls. The area 
under the ROC curve was 0.816; this is interpreted that a 
random patient selected from the AD group would have 
levels of Aβ-oligomers higher that a random individual 
from the control group 81.6% of the time. The 95% 
confidence level between 0.640 and 0.930 is the interval 
in which the true area under the ROC curve lies with 95% 
confidence. The p-value(0.001) is the probability that the 
sample area 0.816 is found when the actual area is 0.5, 
providing evidence that the ELISA does have the ability to 
Figure 6:  Absorbance (450nm) levels from double ELISA performed 
on sera samples from AD patients and age-matched controls.
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distinguish AD patients from controls. The sensitivity of 
the assay is 79.55%.
Lane 2 Aβ42 synthetic peptide
Lanes 3 to 7. Sera of Alzheimer’s patients
Lanes 8 to 11 Sera from age-matched controls
 Results showed that Alzheimer’s sera analysed 
in lanes 3 to 7 contained a faint band cross reacting 
with antibody to Aβ of 14.2kDa, which was not seen in 
control sera. An Aβ oligomer of this molecular size would 
correspond to that of a trimer of Aβ42 (MW 13,542). The 
top of the gel also showed cross reactive material which 
could be higher aggregates. 
Discussion
 It has been established that brain pathological 
changes occur many years before clinical symptoms of 
Alzheimer’s disease develop. This gives opportunity for 
intervention to prevent neurodegeneration taking place, 
using drug therapy or applying behavioural changes, such 
as increased physical exercise. However, for these to be 
applied, it will be necessary to simplify and cut the costs 
of diagnosis so that it may be applied to large populations 
of at risk individuals. Screening programs such as the 
ones required have been applied for early detection of 
other disorders such as faecal testing for bowel cancer. 
PET imaging agents have been developed that show that 
build-up of the protein β-amyloid in brain occurs about 
ten years before cognitive decline shows up in memory 
tests. However the PET imaging procedure is costly, and 
makes use of labile, radioactive agents which may be 
unacceptable to some patients. Aβ has been measured 
in CSF, without differentiation of the state or extent of 
its oligomerisation. Levels appear to be lower in CSF 
when compared to normal controls or patients with other 
dementia types [14]. Phosphorylated tau protein I a 
component of neurofibrillary tangles, seen as intraneuronal 
deposits in post-mortem sections of AD patients. In CSF, 
phosphorylated tau is increased in AD patients compared 
to normal controls. Differences become more pronounced 
when ratios of phosphorylated tau to Aβ are calculated. 
CSF analysis is useful in Alzheimer’s disease detection, 
but is invasive. In contrast, sampling of plasma and serum 
for biochemical markers is the gold standard for diagnostic 
screening, and is readily tolerated by most individuals. 
Most other studies have revealed that levels of total Aβ, 
which would include monomeric forms as well as soluble, 
oligomeric forms in plasma are similar in AD patients 
than in age-matched controls [5]. Thus increases in Aβ 
oligomers are a better indicator of Alzheimer’s Disease 
than monomeric levels, which may indicate that in brain 
these oligomeric species may have toxic actions against 
synaptic connections and neuronal integrity which will if 
left untreated lead to less of cognition. The ELISA assay 
used does not recognise monomeric Aβ, or insoluble Aβ 
fibrils. Further work is required to see if oligomeric species 
are elevated at prodromal or MCI stages of the disease, 
and could therefore be added to a battery of tests aimed 
at defining currently normal individuals who will go on to 
develop AD with time. 
Figure 7: ROC curve of true positive rate (sensitivity) as a function 
of false-positive rate (100-specificity) for different cut-off points for 
oligomer concentrations in sera.
Figure 8: Western blots of sera samples and synthetic peptides using 
6E10 anti Aβ antibodies
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